NCT00882180 - Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

July 31, 2011

Study Completion Date

August 31, 2011

Conditions

Solid Tumors

Interventions

DRUG

ALN-VSP02

IV infusion administered every two weeks

Trial Locations (10)

Memorial Sloan-Kettering Cancer Center, New York

Sarah Cannon Research Institute, Nashville

Hospital Virgen del Rocio, Seville

Hospital Clinico Universitario de Valencia, Valencia

Karmanos Cancer Center, Detroit

TGen Clinical Research Service at Scottsdale Healthcare, Scottsdale

Massachusetts General Hospital, Boston

Dana Farber Cancer Institute, Boston

Beth Israel Deaconess Medical Center, Boston

Hospital Universitario Vall d'Hebron, Barcelona